{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020499","form_type":"8-K","ticker":"TKNO","cik":"0001850902","company_name":"Alpha Teknova, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.230232+00:00","generated_at":"2026-06-15T07:04:35.147956+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.68,"calibrated_materiality_score":0.68,"confidence":"high","headline":"Teknova Q1 revenue $9.1M, down 18% YoY; net loss $8.8M; reaffirms FY23 guidance","bullets":["Q1 total revenue $9.1M, up 16% sequentially but down 18% from $11.1M in Q1 2022.","Net loss $8.8M ($0.31 per diluted share) vs $5.5M loss in Q1 2022; adjusted EBITDA -$6.1M.","Gross margin fell to 26.6% from 48.0% due to lower revenue and fixed cost absorption.","Reaffirmed FY2023 revenue guidance $42-46M and free cash outflow ~$30M.","Launched proprietary AAV-Tek Solutions product line; GMP facility qualification underway toward mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020499","json":"https://secwatch.observer/filing/0000950170-23-020499.json","markdown":"https://secwatch.observer/filing/0000950170-23-020499.md","text":"https://secwatch.observer/filing/0000950170-23-020499.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850902/000095017023020499/0000950170-23-020499-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850902/000095017023020499/tkno-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T07:04:35.147956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a70694b1d02d07f4419013c6aaeb49c4b5455fc","claim":"Alpha Teknova, Inc. reported first quarter ended March 31, 2023 results: revenue $9.1 million, net income $8.8 million, EPS negative $0.31 per diluted share. Guidance reaffirmed.","evidence_excerpt":"First Quarter 2023 Financial Results Total revenue for the first quarter 2023 was $9.1 million, down 18% compared to $11.1 million in the first quarter 2022. Lab Essentials revenue was $7.3 million in the first quarter 2023, up 4% compared to $7.0 million in the first quarter 2022. Clinical Solutions revenue was $1.6 million, down 58% compared to $3.8 million in the first quarter 2022. Gross profit for the first quarter 2023 was $2.4 million, compared to $5.3 million in the first quarter 2022. Gross margin for the first quarter 2023 was 26.6%, compared to 48.0% in the first quarter 2022. The lower gross margin for the first quarter 2023 compared to the first quarter 2022 was primarily driven by the decrease in revenue and the associated lower absorption of fixed manufacturing labor and overhead costs. Operating expenses for the first quarter 2023 were $11.4 million, compared to $11.2 million in the first quarter 2022. Excluding the one-time, non-recurring charge related to the reductio","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850902/000095017023020499/0000950170-23-020499-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$9.1 million"},{"label":"Net income","value":"$8.8 million"},{"label":"EPS","value":"negative $0.31 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}